Wonbiogen KRX:307280KOSDAQ
원바이오젠 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Wonbiogen reported revenue of ₩10.8bn, up 17.0% year on year, and operating profit of ₩2.9bn. Wonbiogen (원바이오젠) appeared in 3 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 10 with 2 articles. The most common catalyst was earnings (1).
Filing signals Op. margin 20%+ Dividend grower Screener
Wonbiogen today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Wonbiogen stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Wonbiogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩10.8bn | +17.0% | ₩2.9bn margin 27.2% | ₩2.3bn |
| Q2 2026 | ₩9.9bn | +18.3% | ₩2.8bn margin 28.0% | ₩2.8bn |
| Q1 2026 | ₩9.3bn | +12.4% | ₩2.1bn margin 22.8% | ₩1.9bn |
| Q4 2025 derived | ₩9.4bn | +10.1% | ₩2.1bn margin 22.4% | ₩1.5bn |
| Q3 2025 | ₩9.2bn | +34.3% | ₩2.4bn margin 26.0% | ₩2.2bn |
| Q2 2025 | ₩8.4bn | +5.0% | ₩1.9bn margin 22.5% | ₩1.4bn |
| Q1 2025 | ₩8.3bn | +16.7% | ₩1.5bn margin 18.6% | ₩1.3bn |
| Q4 2024 derived | ₩8.5bn | +15.4% | ₩1.5bn margin 17.6% | ₩1.3bn |
Wonbiogen ranks #777 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Wonbiogen top stories 2 weeks, by number of outlets
- 1
- 2
Latest Wonbiogen news Korean headlines
-
2026 Wonbio Gen Andong Hoban Ramyun Gran Fondo concludes successfully
1 more on this story · 1 outlets
- 2026 Wonbio Gen Andong Hoban Ramyun Gran Fondo concludes successfully글로벌뉴스통신GNA · Nov 10 16:25
-
Wonbio Biotech presents burn and wound management solutions at Korean Burn Society autumn symposium
1 more on this story · 1 outlets